BRPI0413439A - combinações compreendendo estaurosporinas - Google Patents

combinações compreendendo estaurosporinas

Info

Publication number
BRPI0413439A
BRPI0413439A BRPI0413439-7A BRPI0413439A BRPI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A
Authority
BR
Brazil
Prior art keywords
inhibitor
ihda
flt
malignancies
combinations
Prior art date
Application number
BRPI0413439-7A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Kapil N Bhalla
Pamela Sarah Cohen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0413439A publication Critical patent/BRPI0413439A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçõES COMPREENDENDO ESTAUROSPORINAS". A presente invenção refere-se a um método de tratamento das síndromes mieloplásticas, linfomas e leucemias e também de tumores sólidos com uma combinação farmacêutica de um inibidor da FLT-3 cinase e um inibidor da histona deacetilase (IHDA). Refere-se também ao uso de uma combinação farmacêutica de um inibidor da FLT-3 cinase e de um inibidor da histona deacetilase (IHDA) para o tratamento das doenças e malignidades mencionadas acima e ao uso de uma composição farmacêutica para a fabricação de um medicamento para o tratamento dessas doenças e malignidades.
BRPI0413439-7A 2003-08-08 2004-08-06 combinações compreendendo estaurosporinas BRPI0413439A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49382803P 2003-08-08 2003-08-08
PCT/EP2004/008848 WO2005014004A1 (en) 2003-08-08 2004-08-06 Combinations comprising staurosporines

Publications (1)

Publication Number Publication Date
BRPI0413439A true BRPI0413439A (pt) 2006-10-17

Family

ID=34135288

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413439-7A BRPI0413439A (pt) 2003-08-08 2004-08-06 combinações compreendendo estaurosporinas

Country Status (9)

Country Link
US (1) US20070191338A1 (pt)
EP (2) EP2305265A1 (pt)
JP (1) JP2007501774A (pt)
CN (1) CN100536850C (pt)
AU (1) AU2004262927B2 (pt)
BR (1) BRPI0413439A (pt)
CA (1) CA2533861A1 (pt)
MX (1) MXPA06001524A (pt)
WO (1) WO2005014004A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
CA2617898A1 (en) * 2005-08-09 2007-02-15 Martin Schuler Staurosporine derivatives for treating non-small cell lung cancer
WO2007030455A2 (en) * 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac10
GB0522932D0 (en) * 2005-11-10 2005-12-21 Univ Southampton PKC412 in treatment of atypical chronic myeloid leukemia
GB0612542D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
PL2260020T3 (pl) 2008-03-26 2015-01-30 Novartis Ag Hydroksamianowe inhibitory deacetylaz B
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
US10166241B2 (en) 2012-07-13 2019-01-01 Turun Yliopisto Combination Therapy III

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB8803048D0 (en) 1988-02-10 1988-03-09 Hoffmann La Roche Substituted pyrroles
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
AU2866992A (en) 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
ES2136103T3 (es) 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
PH30300A (en) 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
UA44690C2 (uk) 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU2565795A (en) 1994-06-01 1995-12-21 Ciba-Geigy Ag Carbazole derivatives as agents against multi-drug resistance
WO1995032976A1 (en) 1994-06-01 1995-12-07 Ciba-Geigy Ag Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents
EP0711557A1 (de) 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
NL1003692C2 (nl) 1996-07-26 1998-01-28 Stork Protecon Langen Bv Inrichting voor het afscheiden van vleesmassa van van vleesresten voorziene botten.
CO4940430A1 (es) 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
DE19744676A1 (de) * 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Kombinationspräparate für die Therapie von Tumoren
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) * 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
KR20090087139A (ko) * 2001-10-30 2009-08-14 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
NZ542445A (en) * 2003-04-07 2008-03-28 Pharmacyclics Inc Hydroxamates as therapeutic agents
AU2004241729A1 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents

Also Published As

Publication number Publication date
CN100536850C (zh) 2009-09-09
CN1832747A (zh) 2006-09-13
EP1653973A1 (en) 2006-05-10
CA2533861A1 (en) 2005-02-17
WO2005014004A1 (en) 2005-02-17
EP2305265A1 (en) 2011-04-06
JP2007501774A (ja) 2007-02-01
MXPA06001524A (es) 2006-05-15
AU2004262927B2 (en) 2008-05-22
AU2004262927A1 (en) 2005-02-17
US20070191338A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
IL260127B (en) mek inhibitors and methods of using them
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0115531A (pt) Tratamento de mucosites
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
AU8392501A (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
DE50310516D1 (de) Fredericamycin-derivate
BRPI0507198A (pt) derivados de bisariluréia
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
EA200500782A1 (ru) Лечение геморрагического шока
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
WO2007147613A3 (en) Combinations comprising staurosprorines
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
BR9702200A (pt) Compostos bicíclicos-aromáticos composição farmacéutica composição cosmética e utilização de uma composição cosmética
BRPI0413439A (pt) combinações compreendendo estaurosporinas
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
NO20064753L (no) Kombinasjonsterapi
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
NO20051261L (no) Morfin-6-glukuronidsalt
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
MX2008008470A (es) Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas.
EA202190753A1 (ru) Состав, содержащий озонированное масло, для лечения опухоли

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014.